Cargando…

Characterization of bone metabolism in hungarian psoriatic arthritis patients: a case–control study

BACKGROUND: Skeletal manifestations are predominant in psoriatic arthritis (PsA). The aim of this cross-sectional, case-control study is the complex assessment of areal and volumetric bone mineral density (BMD), fracture risk, vitamin D status and bone turnover markers, and its association with dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Pethő, Zsófia, Kalina, Edit, Pap, Zoltán, Hodosi, Katalin, Falcsik, Rebeka, Balogh, Ádám, Szekanecz, Zoltán, Bhattoa, Harjit Pal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805054/
https://www.ncbi.nlm.nih.gov/pubmed/33435899
http://dx.doi.org/10.1186/s12891-021-03952-z
_version_ 1783636240905535488
author Pethő, Zsófia
Kalina, Edit
Pap, Zoltán
Hodosi, Katalin
Falcsik, Rebeka
Balogh, Ádám
Szekanecz, Zoltán
Bhattoa, Harjit Pal
author_facet Pethő, Zsófia
Kalina, Edit
Pap, Zoltán
Hodosi, Katalin
Falcsik, Rebeka
Balogh, Ádám
Szekanecz, Zoltán
Bhattoa, Harjit Pal
author_sort Pethő, Zsófia
collection PubMed
description BACKGROUND: Skeletal manifestations are predominant in psoriatic arthritis (PsA). The aim of this cross-sectional, case-control study is the complex assessment of areal and volumetric bone mineral density (BMD), fracture risk, vitamin D status and bone turnover markers, and its association with disease-related variables. METHODS: Lumbar spine (L1-L4) and femoral neck (FN) areal, and distal radius (DR) volumetric BMD, 10-year probability of major and hip osteoporotic fracture as assessed by the fracture risk assessment (FRAX) tool, markers of bone metabolism and disease activity were assessed. RESULTS: Upon comparison of the disease and age- and sex-matched control groups, there was a statistically significant difference in FN areal (0.952 (0.607–1.292) g/cm(2) vs. 1.016 (0.760–1.550) g/cm(2); p = 0.001) and DR total volumetric (284.3 (138.9–470.3) mg/cm(3) vs. 367.0 (287.0–412.0) mg/cm(3); p < 0.001) BMD, 10 year probability for major osteoporotic (3.7% (0.7–32%) vs. 2.6% (0–17.5%); p = 0.003) and hip (0.4% (0–16%) vs. 0.05% (0–6.1%); p = 0.002) fracture and 25-hydroxyvitamin D status (47.5 (10–120) nmol/L vs. 64 (10–137; p < 0.001) nmol/L). As compared to areal assessment, volumetric BMD measurements identified a significantly higher number of patients with low bone mineral density (T-Score ≤ − 1.00) (34% vs. 88%, p < 0.001). Upon multiple linear regression analysis, disease activity score, as determined by DAS28 assessment, was an independent predictor of 10-year probability for major osteoporotic fracture (B (95%CI) = 1.351 (0.379–2.323); p = 0.007). CONCLUSION: In the studied PsA cohort, disease activity was an independent predictor of 10-year probability for a major osteoporotic fracture, and complemented assessment of volumetric and areal BMD assured better efficacy at identifying those with low bone mineral density.
format Online
Article
Text
id pubmed-7805054
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78050542021-01-14 Characterization of bone metabolism in hungarian psoriatic arthritis patients: a case–control study Pethő, Zsófia Kalina, Edit Pap, Zoltán Hodosi, Katalin Falcsik, Rebeka Balogh, Ádám Szekanecz, Zoltán Bhattoa, Harjit Pal BMC Musculoskelet Disord Research Article BACKGROUND: Skeletal manifestations are predominant in psoriatic arthritis (PsA). The aim of this cross-sectional, case-control study is the complex assessment of areal and volumetric bone mineral density (BMD), fracture risk, vitamin D status and bone turnover markers, and its association with disease-related variables. METHODS: Lumbar spine (L1-L4) and femoral neck (FN) areal, and distal radius (DR) volumetric BMD, 10-year probability of major and hip osteoporotic fracture as assessed by the fracture risk assessment (FRAX) tool, markers of bone metabolism and disease activity were assessed. RESULTS: Upon comparison of the disease and age- and sex-matched control groups, there was a statistically significant difference in FN areal (0.952 (0.607–1.292) g/cm(2) vs. 1.016 (0.760–1.550) g/cm(2); p = 0.001) and DR total volumetric (284.3 (138.9–470.3) mg/cm(3) vs. 367.0 (287.0–412.0) mg/cm(3); p < 0.001) BMD, 10 year probability for major osteoporotic (3.7% (0.7–32%) vs. 2.6% (0–17.5%); p = 0.003) and hip (0.4% (0–16%) vs. 0.05% (0–6.1%); p = 0.002) fracture and 25-hydroxyvitamin D status (47.5 (10–120) nmol/L vs. 64 (10–137; p < 0.001) nmol/L). As compared to areal assessment, volumetric BMD measurements identified a significantly higher number of patients with low bone mineral density (T-Score ≤ − 1.00) (34% vs. 88%, p < 0.001). Upon multiple linear regression analysis, disease activity score, as determined by DAS28 assessment, was an independent predictor of 10-year probability for major osteoporotic fracture (B (95%CI) = 1.351 (0.379–2.323); p = 0.007). CONCLUSION: In the studied PsA cohort, disease activity was an independent predictor of 10-year probability for a major osteoporotic fracture, and complemented assessment of volumetric and areal BMD assured better efficacy at identifying those with low bone mineral density. BioMed Central 2021-01-12 /pmc/articles/PMC7805054/ /pubmed/33435899 http://dx.doi.org/10.1186/s12891-021-03952-z Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Pethő, Zsófia
Kalina, Edit
Pap, Zoltán
Hodosi, Katalin
Falcsik, Rebeka
Balogh, Ádám
Szekanecz, Zoltán
Bhattoa, Harjit Pal
Characterization of bone metabolism in hungarian psoriatic arthritis patients: a case–control study
title Characterization of bone metabolism in hungarian psoriatic arthritis patients: a case–control study
title_full Characterization of bone metabolism in hungarian psoriatic arthritis patients: a case–control study
title_fullStr Characterization of bone metabolism in hungarian psoriatic arthritis patients: a case–control study
title_full_unstemmed Characterization of bone metabolism in hungarian psoriatic arthritis patients: a case–control study
title_short Characterization of bone metabolism in hungarian psoriatic arthritis patients: a case–control study
title_sort characterization of bone metabolism in hungarian psoriatic arthritis patients: a case–control study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805054/
https://www.ncbi.nlm.nih.gov/pubmed/33435899
http://dx.doi.org/10.1186/s12891-021-03952-z
work_keys_str_mv AT pethozsofia characterizationofbonemetabolisminhungarianpsoriaticarthritispatientsacasecontrolstudy
AT kalinaedit characterizationofbonemetabolisminhungarianpsoriaticarthritispatientsacasecontrolstudy
AT papzoltan characterizationofbonemetabolisminhungarianpsoriaticarthritispatientsacasecontrolstudy
AT hodosikatalin characterizationofbonemetabolisminhungarianpsoriaticarthritispatientsacasecontrolstudy
AT falcsikrebeka characterizationofbonemetabolisminhungarianpsoriaticarthritispatientsacasecontrolstudy
AT baloghadam characterizationofbonemetabolisminhungarianpsoriaticarthritispatientsacasecontrolstudy
AT szekaneczzoltan characterizationofbonemetabolisminhungarianpsoriaticarthritispatientsacasecontrolstudy
AT bhattoaharjitpal characterizationofbonemetabolisminhungarianpsoriaticarthritispatientsacasecontrolstudy